{"schema_version":"secwatch.filing_event.v1","accession":"0001789769-23-000033","form_type":"8-K","ticker":"TIL","cik":"0001789769","company_name":"Instil Bio, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.556459+00:00","generated_at":"2026-06-17T08:12:03.636047+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Instil Bio reports 2022 net loss of $223M; cash runway beyond 2026; ITIL-306 phase 1 in 2H 2023","bullets":["Cash & marketable securities $260.9M (Dec 31, 2022) vs $454.1M in 2021; cash runway beyond 2026 with <$10M quarterly burn from 2H 2023.","Net loss $223.2M in 2022 ($1.72/share) vs $156.8M ($1.48/share) in 2021; restructuring charge $23.2M.","Discontinued ITIL-168 program Dec 2022 over manufacturing issues; prioritized ITIL-306 with anticipated UK MHRA CTA clearance 2H 2023.","Initial ITIL-306 phase 1 clinical data expected in 2024; consolidated R&D ops to Manchester, UK; seeking lease/sale of Tarzana facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001789769-23-000033","json":"https://secwatch.observer/filing/0001789769-23-000033.json","markdown":"https://secwatch.observer/filing/0001789769-23-000033.md","text":"https://secwatch.observer/filing/0001789769-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/til-20230331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:12:03.636047+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44fd68fdf7d92bcce6d0106bd85effc54d48ecea","claim":"Instil Bio, Inc. reported the fourth quarter ended December 31, 2022 results: net income Net loss $ (53,844), EPS Net loss per share, basic and diluted $ (0.41).","evidence_excerpt":"Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"Net loss $ (53,844)"},{"label":"EPS","value":"Net loss per share, basic and diluted $ (0.41)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e9c8752393026c29bac1ff5d5df84c1c383dc950","claim":"Instil Bio, Inc. reported the full year ended December 31, 2022 results: net income Net loss $ (223,177), EPS Net loss per share, basic and diluted $ (1.72).","evidence_excerpt":"Net loss $ (53,844) $ (55,350) $ (223,177) $ (156,794) Net loss per share, basic and diluted $ (0.41) $ (0.43) $ (1.72) $ (1.48)","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1789769/000178976923000033/0001789769-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2022"},{"label":"Net income","value":"Net loss $ (223,177)"},{"label":"EPS","value":"Net loss per share, basic and diluted $ (1.72)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}